Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution - Authors' reply

Affiliations

• ¹ Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg D-69126, Germany; Translational Lung Research Center Heidelberg (TLRCH), German Center for Lung Research (DZL), Heidelberg, Germany. Electronic address: [email protected].
• ² Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals, Leuven, Belgium.
• ³ National Institute for Health Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute Imperial College, London, United Kingdom.
• ⁴ Department of Pulmonary Diseases, Fachkrankenhaus Coswig, Centre for Pulmonary Diseases and Thoracic Surgery, Coswig, Germany.
• ⁵ Firestone Institute for Respiratory Health, Department of Medicine, Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
• ⁶ Policy Analysis Inc. (PAI), MINERVA Health Economics Network, Ltd., Brookline, MA, USA.
• ⁷ Medical University Clinic, Kanton Hospital Baselland and University of Basel, Liestal, Switzerland.
• ⁸ F Hoffmann-La Roche Ltd, Basel, Switzerland.
• ⁹ Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg D-69126, Germany; Translational Lung Research Center Heidelberg (TLRCH), German Center for Lung Research (DZL), Heidelberg, Germany.
• ¹⁰ Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, University Hospital, University of Duisburg- Essen, Essen, Germany.